- Home
- INMB vs IRD Comparison
INMB vs IRD Comparison
Compare INMB & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- IRD
- Stock Information
- Founded
- INMB 2015
- IRD 2018
- Country
- INMB United States
- IRD United States
- Employees
- INMB N/A
- IRD N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- IRD
- Sector
- INMB Health Care
- IRD
- Exchange
- INMB Nasdaq
- IRD NYSE
- Market Cap
- INMB 68.9M
- IRD 59.1M
- IPO Year
- INMB 2019
- IRD N/A
- Fundamental
- Price
- INMB $2.91
- IRD $1.18
- Analyst Decision
- INMB Buy
- IRD Strong Buy
- Analyst Count
- INMB 4
- IRD 3
- Target Price
- INMB $9.53
- IRD $6.33
- AVG Volume (30 Days)
- INMB 4.5M
- IRD 261.1K
- Earning Date
- INMB 08-04-2025
- IRD 08-15-2025
- Dividend Yield
- INMB N/A
- IRD N/A
- EPS Growth
- INMB N/A
- IRD N/A
- EPS
- INMB N/A
- IRD N/A
- Revenue
- INMB $50,000.00
- IRD $13,651,000.00
- Revenue This Year
- INMB $203.60
- IRD $51.41
- Revenue Next Year
- INMB $13,122.47
- IRD $68.84
- P/E Ratio
- INMB N/A
- IRD N/A
- Revenue Growth
- INMB N/A
- IRD N/A
- 52 Week Low
- INMB $1.89
- IRD $0.65
- 52 Week High
- INMB $11.64
- IRD $2.09
- Technical
- Relative Strength Index (RSI)
- INMB 41.06
- IRD N/A
- Support Level
- INMB $2.62
- IRD N/A
- Resistance Level
- INMB $3.07
- IRD N/A
- Average True Range (ATR)
- INMB 0.25
- IRD 0.00
- MACD
- INMB 0.24
- IRD 0.00
- Stochastic Oscillator
- INMB 72.26
- IRD 0.00
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.